A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of AZD1775 on the Pharmacokinetics of Substrates for CYP3A, CYP2C19, CYP1A2 and to Provide Data on the Effect of AZD1775 on QT Interval in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2018
At a glance
- Drugs Adavosertib (Primary) ; Caffeine; Granisetron; Midazolam; Omeprazole
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 01 Oct 2018 Planned number of patients changed from 30 to 52.
- 01 Oct 2018 Planned End Date changed from 22 Aug 2018 to 28 Jun 2019.
- 01 Oct 2018 Planned primary completion date changed from 22 Aug 2018 to 28 Jun 2019.